CAMBRIDGE, Mass. — Convergent Therapeutics Inc. announced that data from its ongoing Phase 2 clinical trial of CONV01-α will be presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago.
The oral presentation, scheduled for June 1, will focus on safety and efficacy results in patients with metastatic castration-resistant prostate cancer who were previously treated with Lu-177 PSMA radioligand therapy.
“We appreciate the opportunity to share these data at ASCO and to contribute to the discussion around how prostate cancer treatment is evolving,” said Philip Kantoff, MD, chief executive officer and co-founder of Convergent Therapeutics. “As targeted radiotherapies become more integrated into care, there is growing focus on how to extend benefit for patients who have already received Lu-177 PSMA radioligand therapy and need further options. This is an important emerging challenge in mCRPC, and one that will help define the next phase of progress in the field.”
The presentation will highlight findings from the CONVERGE-01 trial evaluating a PSMA-targeted actinium-225 radioantibody therapy. The company said the study is aimed at addressing treatment gaps for patients whose disease has progressed after prior radioligand therapy.
Michael J. Morris, MD, section head of prostate cancer at Memorial Sloan Kettering Cancer Center, is scheduled to deliver the presentation during a clinical science symposium focused on innovations in radioligand therapy for prostate cancer.
